Physician profile
William E Schemmel
NPI 1063419935
$2,013.91
in general payments reported to CMS, 2019-2025
18 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $295 · 2021: $64.02 · 2022: $115 · 2023: $205 · 2024: $496 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.08 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $418.74 | 2020-2025 | Ora System Verifeye, Clareon, Rocklatan |
| Abbvie INC. | $300.86 | 2023-2025 | Durysta |
| Apellis Pharmaceuticals, INC. | $209.77 | 2023-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $201.71 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $190.71 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $160.46 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Oyster Point Pharma, INC. | $97.85 | 2023-2024 | Tyrvaya |
| Biotissue Holdings INC. | $60.23 | 2024-2025 | |
| Carl Zeiss Meditec, INC. | $50.00 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $39.81 | 2024-2025 | Xdemvy |
| Rxsight INC | $38.25 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Horizon Therapeutics Plc | $37.95 | 2022-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $35.13 | 2023 | Miebo, Vyzulta |
| Rayner Intraocular Lenses Limited | $22.38 | 2024 | Omidria |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $18.38 | 2024 | Oxervate |
| Mallinckrodt Hospital Products INC. | $17.00 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $14.68 | 2023 | Tecnis Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Schemmel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.